Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner may stop autoimmune disease before it starts

NCT ID NCT05098704

Recruiting now Prevention Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether clopidogrel, a common blood thinner, can prevent systemic sclerosis (scleroderma) in people who have Raynaud phenomenon and specific antibodies that put them at high risk. About 47% of such individuals develop full scleroderma within five years. Participants take either clopidogrel or a placebo daily for two years, and researchers track how many develop the disease over five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
clopidogrel
What this could lead to
If it works, this could be the first preventive treatment to stop scleroderma from developing in people with early warning signs.
What could go wrong
This is a mid-stage trial with only 90 participants, so results may not apply widely. Clopidogrel is a blood thinner and carries a risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma scleroderma systemic sclerosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLERODERMA SYSTEMIC SCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • AP-HP - Hôpital Cochin - service de médecine interne

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

    Contact

  • CH de Libourne - service de rhumatologie

    RECRUITING

    Libourne, France

    Contact Email: •••••@•••••

    Contact

  • CH de Mont-de-Marsan - service de rhumatologie

    RECRUITING

    Mont-de-Marsan, France

    Contact Email: •••••@•••••

    Contact

  • CH de Pau - service de médecine interne

    RECRUITING

    Pau, France

    Contact Email: •••••@•••••

    Contact

  • CH de la Cote Basque - service de rhumatologie

    RECRUITING

    Bayonne, France

    Contact Email: •••••@•••••

    Contact

  • CHU de Bordeaux - service de Médecine Interne et Maladies Infectieuses

    NOT_YET_RECRUITING

    Bordeaux, France

    Contact Email: •••••@•••••

    Contact

  • CHU de Bordeaux - service de rhumatologie

    RECRUITING

    Bordeaux, France

    Contact

    Contact

    Contact

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact Email: •••••@•••••

  • CHU de Brest - service de rhumatologie

    RECRUITING

    Brest, France

    Contact Email: •••••@•••••

    Contact

  • CHU de Grenoble Alpes - service de médecine vasculaire

    RECRUITING

    Grenoble, France

    Contact Email: •••••@•••••

    Contact

  • CHU de Toulouse - service de médecine interne

    NOT_YET_RECRUITING

    Toulouse, France

    Contact Email: •••••@•••••

    Contact

  • Service de Médecine Interne et Immunologie Clinique

    NOT_YET_RECRUITING

    Rennes, France

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.